Rapid eye movement sleep behaviour disorder (R.B.D.) is a relatively new diagnosis, first described in the mid-1980s.' These case reports describe two psychiatric outpatients who presented with typical features of the disorder and who had an effective response to treatment with clonazepam. In one instance the patient had undergone several medical evaluations, including a sleep EEG, but without a definite diagnosis being reached. Both patients were diagnosed on clinical grounds, and showed a positive response to clonazepam. In both cases they experienced recurrence of symptoms of R.B.D. after discontinuation or dose reduction and improved again after rechallenge with clonazepam. This paper highlights the need for clinicians to He also commented himself that he would feel "sore all over on awakening" and that the nightmares involved a frightening image of "chasing or fighting with a female" figure. By May, 2000 the patient' s mood had begun to show signs of relapse, despite claiming compliance with the citalopram, with recurrence of agitation and initial insomnia along with anhedonia. Accordingly the citalopram was replaced with mirtazapine 30mg nocte. In September, 2000 his depression had improved to a sufficient extent to allow discharge from the day hospital. To date, the patient has been followed at a psychiatry outpatient clinic and continues to maintain improved sleep pattern from clonazepam 1mg nocte, which he generally complies with despite ongoing complaints of a slightly sedated "hungover" feeling in the mornings; this he attributes to the medication. It as it will allow full overnight monitoring of the patient. This should also be available at most district general hospitals, rather than requiring referral to specialist tertiary care hospitals. These cases also illustrate the ready response of this disorder to low dose clonazepam, ranging between 0.25mg and 1mg here, with marked improvement in the quality of life for the patients and their spouses. The authors believe that a reasonable practice would be, in the first instance and on clinical grounds to make a diagnosis of R.B.D. and to initiate a trial of clonazepam, with evaluation of clinical response. Further tests such as sleep EEG could be reserved for cases which do not show a response to the usually effective doses of clonazepam, or which are atypical in other ways. This report also describes a potential difficulty with clonazepam in this age group, namely an adverse side-effect of sedation which may have implications for compliance and require psychoeducation on the part of the physician treating these patients. A final point is that R.B.D. should always be considered as part of the differential diagnosis in elderly patients with nocturnal wandering and falls.
